GSK PLC Sponsored ADR (NYSE:GSK) Receives $44.13 Average Target Price from Analysts

GSK PLC Sponsored ADR (NYSE:GSK) has been assigned an average recommendation of “Reduce” from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $44.1250.

A number of research firms recently weighed in on GSK. Bank of America raised shares of GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a research note on Friday, January 16th. Wall Street Zen cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, January 14th. Finally, HSBC reaffirmed a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK struck a global licensing deal for linerixibat with Italy’s Alfasigma that delivers $300M upfront and up to roughly $690M in total consideration plus tiered double‑digit royalties — a near‑term cash boost and lower commercialization cost for a late‑stage asset. GSK licenses liver disease drug to Italy’s Alfasigma
• Positive Sentiment: Short interest fell sharply in February (down ~17.3% to ~10.8M shares, ~0.6% of float; days‑to‑cover ~1.8), reducing potential short‑selling pressure and the likelihood of short‑covering squeezes that can amplify downside volatility.
• Neutral Sentiment: Analyst/commentary pieces highlight GSK’s strong run over the past year (roughly +40%+) and debate whether valuation leaves room for further upside — useful context for investors weighing new positions. Is It Too Late to Buy GSK After a 46% Share Price Jump?
• Neutral Sentiment: Coverage noting GSK’s manufacturing strengths and pipeline focus may support a longer‑term investment thesis but is unlikely to move the stock immediately. Manufacturing Prowess Emerges as Key GSK Investment Theme
• Negative Sentiment: The upside from the linerixibat transaction is conditional — the US approval decision is pending and further milestone payments depend on regulatory outcomes and commercial performance; a negative FDA decision would erase the approval‑linked upside. GSK Out‑Licenses Rights for Rare Liver Disease Drug to Alfasigma

Insider Activity at GSK

In related news, major shareholder Plc Gsk purchased 1,470,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This represents a 8.76% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.00% of the stock is owned by insiders.

Institutional Trading of GSK

Large investors have recently added to or reduced their stakes in the stock. IHT Wealth Management LLC raised its position in GSK by 1.3% in the fourth quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock worth $736,000 after acquiring an additional 188 shares during the period. Coston McIsaac & Partners increased its stake in shares of GSK by 17.3% during the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after purchasing an additional 206 shares during the last quarter. First Horizon Corp increased its stake in shares of GSK by 78.7% during the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 236 shares during the last quarter. TOWER TRUST & INVESTMENT Co raised its holdings in shares of GSK by 1.3% in the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 23,195 shares of the pharmaceutical company’s stock worth $1,001,000 after purchasing an additional 293 shares during the period. Finally, Peoples Bank KS lifted its stake in GSK by 6.3% in the fourth quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock valued at $247,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

GSK opened at $55.31 on Friday. GSK has a 1 year low of $32.38 and a 1 year high of $61.69. The company has a debt-to-equity ratio of 0.92, a current ratio of 0.82 and a quick ratio of 0.54. The company has a market capitalization of $112.72 billion, a price-to-earnings ratio of 14.95, a P/E/G ratio of 3.36 and a beta of 0.44. The firm’s fifty day moving average price is $54.16 and its two-hundred day moving average price is $48.08.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 9th. Stockholders of record on Friday, February 20th will be given a dividend of $0.4856 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $1.94 annualized dividend and a dividend yield of 3.5%. This is a boost from GSK’s previous quarterly dividend of $0.42. GSK’s payout ratio is 51.62%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.